How Do GLP-1 Medications Work in Australia? TGA Approval, PBS Coverage, and Real Costs

Direct Answer

In Australia, GLP-1 medications are regulated by the Therapeutic Goods Administration (TGA), roughly equivalent to the FDA, and subsidized coverage runs through the Pharmaceutical Benefits Scheme (PBS). Ozempic is both TGA-approved and PBS-listed for type 2 diabetes, meaning genuine subsidized access exists. Wegovy, while TGA-approved, was not yet PBS-listed for obesity as of early 2026, a real, important gap that leaves most Australians paying full, unsubsidized cost for it.

The Real Cost Gap Worth Knowing

Without PBS subsidy, brand-name GLP-1 medications in Australia run roughly $350 to $600 per month out of pocket. This creates a genuinely real, practical divide: people with type 2 diabetes prescribed Ozempic get subsidized pricing, while people seeking the same broad medication class specifically for weight management often don't, since Wegovy's obesity indication hadn't cleared PBS listing as of this writing.

Mounjaro and Zepbound Status

Mounjaro is TGA-approved, with PBS listing status still evolving. Worth checking current, updated status directly, since this is a genuinely fast-moving area of Australian drug policy.

Bottom Line

If you're in Australia, the real, practical question isn't just "is this medication approved," it's "is it PBS-listed for my specific reason for taking it," since TGA approval and PBS subsidy are two separate steps, and the gap between them is exactly where real, unsubsidized cost differences show up.

References

• Regimen: How to Get GLP-1 Medications by Country (2026)

Explore More

Explore the full GLP-1 Tracker knowledge base on DietApp.com

Get Started

Explore the GLP-1 Tracker knowledge base for accurate, sourced information on every GLP-1 medication.

About DietApp.com

DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. This article is for general informational purposes and is not medical advice.